[go: up one dir, main page]

EP2139470A4 - Compositions de docétaxel nanoparticulaires stérilisées par rayonnement gamma et procédés de fabrication associés - Google Patents

Compositions de docétaxel nanoparticulaires stérilisées par rayonnement gamma et procédés de fabrication associés

Info

Publication number
EP2139470A4
EP2139470A4 EP08732593A EP08732593A EP2139470A4 EP 2139470 A4 EP2139470 A4 EP 2139470A4 EP 08732593 A EP08732593 A EP 08732593A EP 08732593 A EP08732593 A EP 08732593A EP 2139470 A4 EP2139470 A4 EP 2139470A4
Authority
EP
European Patent Office
Prior art keywords
nanoparticular
methods
gamma radiation
making same
radiation sterilized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08732593A
Other languages
German (de)
English (en)
Other versions
EP2139470A2 (fr
Inventor
H William Bosch
Janine Keller
Niels Ryde
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perrigo Pharma International DAC
Original Assignee
Elan Pharma International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma International Ltd filed Critical Elan Pharma International Ltd
Publication of EP2139470A2 publication Critical patent/EP2139470A2/fr
Publication of EP2139470A4 publication Critical patent/EP2139470A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP08732593A 2007-03-23 2008-03-20 Compositions de docétaxel nanoparticulaires stérilisées par rayonnement gamma et procédés de fabrication associés Withdrawn EP2139470A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89664707P 2007-03-23 2007-03-23
PCT/US2008/057701 WO2008118754A2 (fr) 2007-03-23 2008-03-20 Compositions de docétaxel nanoparticulaires stérilisées par rayonnement gamma et procédés de fabrication associés

Publications (2)

Publication Number Publication Date
EP2139470A2 EP2139470A2 (fr) 2010-01-06
EP2139470A4 true EP2139470A4 (fr) 2010-07-28

Family

ID=39789241

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08732593A Withdrawn EP2139470A4 (fr) 2007-03-23 2008-03-20 Compositions de docétaxel nanoparticulaires stérilisées par rayonnement gamma et procédés de fabrication associés

Country Status (4)

Country Link
EP (1) EP2139470A4 (fr)
JP (1) JP2010522207A (fr)
CA (1) CA2680106A1 (fr)
WO (1) WO2008118754A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008291930B2 (en) * 2007-08-24 2014-04-17 Slotervaart Participaties Bv Compositions for the treatment of neoplastic diseases
US9089544B2 (en) 2007-08-24 2015-07-28 Slotervaart Participaties Bv Composition
CA2763456C (fr) * 2009-05-27 2017-10-24 Alkermes Pharma Ireland Limited Reduction de l'agregation a l'origine de paillettes dans des compositions a base d'un principe actif nanoparticulaire
KR101800036B1 (ko) 2009-11-04 2017-11-22 메르크 파텐트 게엠베하 액정 매질용 화합물, 및 고주파 부품을 위한 그의 용도
KR102303762B1 (ko) 2017-06-14 2021-09-23 크리티테크, 인크. 폐 장애의 치료 방법
JP2021524505A (ja) * 2018-05-19 2021-09-13 ゲイリー ビンヤミン, 発泡体製剤および身体への送達法
CN114712316B (zh) * 2020-12-18 2023-10-20 江苏恒瑞医药股份有限公司 一种难溶性药物组合物及制备方法
US12083081B2 (en) * 2021-04-29 2024-09-10 Protara Therapeutics, Inc. Sterile aqueous choline salt compositions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5302401A (en) * 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US20040105778A1 (en) * 2002-10-04 2004-06-03 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
US20060188566A1 (en) * 2005-02-24 2006-08-24 Elan Pharma International Limited Nanoparticulate formulations of docetaxel and analogues thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU739303B2 (en) * 1997-08-21 2001-10-11 Florida State University Method for the synthesis of taxanes
GB9820457D0 (en) * 1998-09-18 1998-11-11 Medlogic Global Corp Methods for sterilizing cyanoacrylate compositions
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6342249B1 (en) * 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US20020141966A1 (en) * 2000-11-16 2002-10-03 Wenbin Dang Compositions for treatment of malignant effusions, and methods of making and using the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5302401A (en) * 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US20040105778A1 (en) * 2002-10-04 2004-06-03 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
US20060188566A1 (en) * 2005-02-24 2006-08-24 Elan Pharma International Limited Nanoparticulate formulations of docetaxel and analogues thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MERISKO-LIVERSIDGE E ET AL: "Nanosizing: A formulation approach for poorly-water-soluble compounds", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES FEBRUARY 2003 ELSEVIER NL, vol. 18, no. 2, February 2003 (2003-02-01), pages 113 - 120, XP002586752, DOI: 10.1016/S0928-0987(02)00251-8 *

Also Published As

Publication number Publication date
JP2010522207A (ja) 2010-07-01
CA2680106A1 (fr) 2008-10-02
EP2139470A2 (fr) 2010-01-06
WO2008118754A2 (fr) 2008-10-02
WO2008118754A3 (fr) 2009-12-30

Similar Documents

Publication Publication Date Title
NO20200775A1 (no) Fremgangsmåter og sammensetninger for behandling av kreft
EP2139470A4 (fr) Compositions de docétaxel nanoparticulaires stérilisées par rayonnement gamma et procédés de fabrication associés
CY2020042I2 (el) Αντιδοτα για τους αναστολεις του παραγοντα χα και μεθοδοι χρησεως αυτων
CY2019010I1 (el) Νεες ενωσεις και συνθεσεις και μεθοδοι χρησης
DK2473034T3 (da) Frøbehandlingssammensætninger og fremgangsmåde
CY2014026I2 (el) Συνθεσεις και χρησεις για θεραπεια σκληρυνσης κατα πλακας
EP2331155A4 (fr) Biocomposites et leurs procédés de fabrication
EP2413693A4 (fr) Dérivés d'azoanthracène substitués, compositions pharmaceutiques et leurs procédés d'utilisation
PL2144998T3 (pl) Sposoby i kompozycje dla żywych atenuowanych wirusów
EP2214597A4 (fr) Implants rachidiens et procédés
DE602007008066D1 (de) Polyethylenzusammensetzungen und daraus hergestelltes rohr
FR2977139B1 (fr) Implant inter-epineux et instrument d’implantation
EP2506967A4 (fr) Composition de nanoparticules et ses procédés de préparation
EP2002263A4 (fr) Compositions d'immunothérapie pour cancer et méthodes d'utilisation
EP2400921A4 (fr) Implants orthopédiques personnalisés et procédés associés
EP2904094A4 (fr) Compositions micronisées composées de greffons osseux et leurs procédés de fabrication et d'utilisation
BRPI0906980A2 (pt) Composição de derivados e maleatados
BRPI0812562A2 (pt) composições terapêuticas anti-cd20 e métodos
EP2230906A4 (fr) Compositions d'anidulafungine nanoparticulaires et leurs procédés de fabrication
EP2302664A4 (fr) Appareil multi-colonnes d exposition par faisceau d électrons et appareil générateur de champ magnétique
DK2154966T3 (da) Benzimidazoler og farmaceutiske sammensætninger deraf
EP2365978A4 (fr) Compositions de lécithine et de plastifiant et procédés
BRPI0918206A2 (pt) derivados de animoéster e composição medicinal destes
SMT201700084B (it) Associazioni antineoplastiche di 4-anilino-3-cianochinoline e capecitabina
ITTO20110641A1 (it) Composizioni farmaceutiche e metodi di trattamento

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20091020

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

R17D Deferred search report published (corrected)

Effective date: 20091230

RIC1 Information provided on ipc code assigned before grant

Ipc: A61L 2/00 20060101AFI20100115BHEP

Ipc: A61N 5/00 20060101ALI20100115BHEP

Ipc: A61K 31/335 20060101ALI20100115BHEP

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/19 20060101ALI20100614BHEP

Ipc: A61K 9/14 20060101ALI20100614BHEP

Ipc: A61K 31/337 20060101AFI20100614BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20100629

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1140408

Country of ref document: HK

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20120222

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120704

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1140408

Country of ref document: HK